A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Public ClinicalTrials.gov record NCT01617668. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Study identification
- NCT ID
- NCT01617668
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 209 participants
Conditions and interventions
Conditions
Interventions
- LCL161 Drug
- paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2012
- Primary completion
- Aug 31, 2014
- Completion
- Aug 31, 2014
- Last update posted
- Oct 16, 2016
2012 – 2014
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group Dept of Highlands Oncology Grp | Fayetteville | Arkansas | 72703 | — |
| Cedars Sinai Medical Center SC | Los Angeles | California | 90048 | — |
| University of California at Los Angeles UCLA SC | Los Angeles | California | 90095 | — |
| Stanford University Medical Center Stanford | Stanford | California | 94304 | — |
| Yale University School of Medicine Yale Univ | New Haven | Connecticut | 06520 | — |
| H. Lee Moffitt Cancer Center & Research Institute H. Lee Moffitt SC | Tampa | Florida | 33612 | — |
| Massachusetts General Hospital Mass General 2 | Boston | Massachusetts | 02114 | — |
| Memorial Sloan Kettering Cancer Center Dept Onc | New York | New York | 90033 | — |
| Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State | Columbus | Ohio | 43210 | — |
| Vanderbilt University Medical Center Vanderbilt - Thompson Ln | Nashville | Tennessee | 37232 | — |
| Baylor College of Medicine Dept of Oncology | Houston | Texas | 77030 | — |
| Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5) | San Antonio | Texas | 78229 | — |
| University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 2 | Madison | Wisconsin | 53792-6164 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01617668, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2016 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01617668 live on ClinicalTrials.gov.